Canada markets closed
  • S&P/TSX

    19,040.78
    -163.64 (-0.85%)
     
  • S&P 500

    4,134.94
    -28.32 (-0.68%)
     
  • DOW

    33,821.30
    -256.33 (-0.75%)
     
  • CAD/USD

    0.7930
    -0.0052 (-0.65%)
     
  • CRUDE OIL

    62.61
    +0.17 (+0.27%)
     
  • BTC-CAD

    71,352.81
    +572.62 (+0.81%)
     
  • CMC Crypto 200

    1,296.41
    +62.00 (+5.02%)
     
  • GOLD FUTURES

    1,778.20
    -0.20 (-0.01%)
     
  • RUSSELL 2000

    2,188.21
    -43.79 (-1.96%)
     
  • 10-Yr Bond

    1.5620
    -0.0390 (-2.44%)
     
  • NASDAQ futures

    13,753.50
    -40.75 (-0.30%)
     
  • VOLATILITY

    18.68
    +1.39 (+8.04%)
     
  • FTSE

    6,859.87
    -140.21 (-2.00%)
     
  • NIKKEI 225

    29,100.38
    -584.99 (-1.97%)
     
  • CAD/EUR

    0.6586
    -0.0041 (-0.62%)
     

Aion Therapeutic Names James W.G. Thompson, Ph.D. as President

  • Oops!
    Something went wrong.
    Please try again later.
Newsfile Corp.
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.

Neuroscientist, Healthcare Technology Entrepreneur to Lead Aion Through Important Next Phase

Toronto, Ontario--(Newsfile Corp. - October 21, 2020) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that the Company has named James W.G. Thompson, Ph.D. as its new president.

Dr. Thompson is an accomplished neuroscientist and healthcare technology entrepreneur with over 20 years industry experience. Most recently he co-founded Evoke Neuroscience, Inc., a healthcare technology company founded in 2009 and focused on aiding diagnosis and therapy for neurological disorders. Dr. Thompson served on the Board of Directors for 10 years and held roles as Chief Science Officer, Chief Technology Officer and Chief Innovation Officer. He has led early and mid-stage companies in multiple verticals including mental health, brain injury, neuro-degeneration, cardiology and wellness, covering medical devices, software, clinical research, therapeutics, regulatory, AI and big data.

Dr. Thompson's work specializes in the research, development, application, market strategy and commercialization of biotech and he is a principal inventor on 13 awarded patents and 3 pending patents related to data analytics, remote database systems, medical hardware, medical software and neuromodulation.

"Dr. Thompson's accomplishments, experience and skill-set makes him an ideal selection as our new president," stated Dr. Stephen D. Barnhill, Executive Chair of Aion. "His expertise directly aligns with our intentions and his practical business expertise and relationships are accretive to Aion's interests."

"I am thrilled to join the talented team at Aion," stated Dr. Thompson. "The technology assembled under the Aion banner is unparalleled in my estimation and I am looking forward to working with this team and helping officiate this tremendous opportunity."

About Aion Therapeutic Inc.

Aion Therapeutic Inc. (formerly, Osoyoos Cannabis Inc.) has a joint-venture agreement with a private, vertically-integrated licensed producer under the Cannabis Act (Canada) to offer contract tolling extraction services to third-party businesses. Additionally, the Company recently acquired 1196691 B.C. Ltd. d/b/a "PCAI Pharma" (www.pcai.ca) and its wholly-owned subsidiary AI Pharmaceuticals Jamaica Limited, a private corporation incorporated and operating under the laws of Jamaica. The business of AI Pharma involves, research and development, treatment, data mining and state-of-the-art artificial intelligence (machine learning) techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals utilizing compounds from cannabis (cannabinoids), psychedelic mushrooms (psilocybin), fungi (edible mushroom), natural psychedelic formulations (Ayahuasca), and other medicinal plants in a legal environment for this type of discovery. In addition, the Company is creating a strong international intellectual property portfolio related to their discoveries.

For further information, please contact:

Investor Relations & Financial Media
Integrity Media Inc.

team@integritymedia.com

Toll Free: (888) 216-3595
www.IntegrityMedia.com

Aion Therapeutic Inc.
Graham Simmonds
Executive Vice Chair & CEO

(416) 843-2881

DISCLAIMER & READER ADVISORY

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "may", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the parties. The material factors and assumptions include regulatory and other third-party approvals; licensing and other risks. The forward-looking information contained in this release is made as of the date hereof and the parties are not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/66491